How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Do you ever escalate therapy before 12 months of ursodeoxycholic acid in patients with normal bilirubin but persistent ALP >1.67×ULN and significant symptoms, and if so what early-response or baseline features trigger that earlier escalation?

How do you choose between a PPAR agonist, obeticholic acid, or a fibrate as second-line therapy in PBC with optimized ursodeoxycholic acid when the immediate priority is clinically significant pruritus but you also want to optimize long-term biochemical risk reduction?

What criteria do you use to transition a PSC patient from on-demand ERCP to a scheduled dilation program, and which patient features best predict meaningful clinical benefit rather than simply more procedures?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.